FDA Approves Manufacturing Plan For Menerba, Bionovo's Menopausal Hot Flash Drug Candidate
October 29, 2010 by · Leave a Comment
Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba®, in a Type “B” or “End of Phase 2″ meeting. With this designation, the decisions and agreements are now considered binding on the Company and the FDA…
FDA Approves Manufacturing Plan For Menerba, Bionovo's Menopausal Hot Flash Drug Candidate
October 24, 2010 by · Leave a Comment
Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba®, in a Type “B” or “End of Phase 2″ meeting. With this designation, the decisions and agreements are now considered binding on the Company and the FDA…
FDA Approves Manufacturing Plan For Menerba, Bionovo's Menopausal Hot Flash Drug Candidate
October 18, 2010 by · Leave a Comment
Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba®, in a Type “B” or “End of Phase 2″ meeting. With this designation, the decisions and agreements are now considered binding on the Company and the FDA…
FDA Approves Manufacturing Plan For Menerba, Bionovo's Menopausal Hot Flash Drug Candidate
October 16, 2010 by · Leave a Comment
Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba®, in a Type “B” or “End of Phase 2″ meeting. With this designation, the decisions and agreements are now considered binding on the Company and the FDA…
FDA Approves Manufacturing Plan For Menerba, Bionovo's Menopausal Hot Flash Drug Candidate
October 5, 2010 by · Leave a Comment
Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba®, in a Type “B” or “End of Phase 2″ meeting. With this designation, the decisions and agreements are now considered binding on the Company and the FDA…
